Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DGAT2 Double Nickase Plasmid (h): sc-416229-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DGAT2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DGAT2 Double Nickase Plasmid (h) and DGAT2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DGAT2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DGAT2 Antibody (4C1): sc-293211
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DGAT2 Double Nickase Plasmid (h) | sc-416229-NIC | 20 µg | $410.00 | |||
DGAT2 Double Nickase Plasmid (h2) | sc-416229-NIC-2 | 20 µg | $410.00 |
DGAT2 (diacylglycerol O-acyltransferase 2) encodes an endoplasmic reticulum–associated enzyme that catalyzes the final, committed step of triacylglycerol synthesis by acylating diacylglycerol with fatty acyl-CoA. As a core component of neutral lipid production, DGAT2 supports lipid droplet biogenesis and integrates with glycerolipid metabolism, fatty acid flux, and energy storage pathways. Altered DGAT2 activity is linked to dysregulated hepatic and adipose lipid handling and has been studied in the context of metabolic disease mechanisms, including steatosis, insulin resistance–associated lipid remodeling, and obesity-related phenotypes. DGAT2 is also used as a functional node to interrogate lipotoxic stress responses and ER homeostasis during excess lipid loading.
DGAT2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DGAT2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DGAT2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DGAT2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DGAT2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.